RxDoctor Payments Data

Daniel Ladd

Physician Assistant · Traverse City, MINPI 1689669251

Payments from drug & device makers

$587in general payments, 2019–2025

Across 13 payments — averaging $45.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$215
  • Boehringer Ingelheim$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$101
  • AbbVie$54
  • Otsuka America Pharmaceutical, Inc.$33
  • Argenx US, Inc.$25
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$40268%
  • Education$18532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$587 in reported general payments places this provider in the 65th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$15,620
Medicare patients
75
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept99$712,231
Humira(Cf) PenAdalimumab45$438,217
Humira(Cf)Adalimumab21$182,788
RinvoqUpadacitinib25$153,363
Orencia ClickjectAbatacept24$146,488
Cosentyx Unoready PenSecukinumab12$141,628
Xeljanz XrTofacitinib Citrate21$114,575
EnbrelEtanercept14$99,166
XeljanzTofacitinib Citrate16$90,505
Hydroxychloroquine Sulfate285$16,885
MethotrexateMethotrexate Sodium440$12,951
Cevimeline Hcl21$3,470
Leflunomide82$3,277
Prednisone193$1,358
Pilocarpine Hcl18$1,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Rinvoq$54$336,15246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →